Association of survivin splice variants with prognosis and treatment of breast cancer

Table 3 Summarized data for research articles, which correlated survivin isoforms with breast cancer treatment

Ref.	Examined variants	Methods	Approaches for inhibition of survivin variants	Conclusion
Yamanaka et al[55]	wt, sur2b, surΔΕx3, sur3b	Real time qPCR	YM155	Survivin suppressing activity of YM155 may offer novel therapeutic option in TNBC
Boidot et al[57]	wt, sur2b, surΔΕx3, sur3b, sur2a	Real time qPCR	FEC/Tax-Epi	Alternative survivin transcript expression levels may be predictive markers in FEC and Tax-Epi treatment
Zheng et al[58]	wt, sur2b, surΔΕx3	MMT, flow cytmetry	Recombinant plasmids pGEM-T	Feasibility of targeting wt and surΔΕx3 in treating breast cancer

wt: Wild-type surviving; sur2b: Survivin-2b; surΔΕx3: Survivin-ΔΕx3; sur3b: Survivin-3b; sur2a: Survivin-2a; MMT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; YM155: Sepantronium bromide; FEC: 5-fluorouracil + epirubicin + cyclophosphamide; Tax-Epi: Docetaxel + epirubicin; TNBC: Triple negative breast cancer.